T2EVOLVE is a breakthrough alliance of academic and industry leaders in cancer immunotherapy which started in January 2021, under the European Union’s Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and to increase access of cancer patients to immunotherapy with reprogrammed immune cells. Reprogramming is accomplished by genetic engineering with a T cell receptor (TCR) or synthetic chimeric antigen receptor (CAR).
